Thomas Jefferson University: Prostatic Neoplasms trials

The registry lists 14 Prostatic Neoplasms studies with Thomas Jefferson University as lead sponsor. 4 are open to participants now and 1 have results posted.

Phase 1 1Phase 2 3Phase 3 2No phase 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• LuX: Xaluritamig in Participants With Metastatic Castrate Resistant Prostate Cancer and Suboptimal Response to Lutetium 177 Vipivotide TetraxetanNot yet recruitingNCT07737925Phase 2
• Multiparametric Ultrasound for the Diagnosis of Clinically Significant Prostate CancerNot yet recruitingNCT06024772Phase 3
• Extending Prostate Genetic Awareness, Navigation, and Delivery: The EXPAND NetworkRecruitingNCT05627219
• Peer Navigation for the Support of Metastatic Prostate Cancer Patients Undergoing Genetic EvaluationRecruitingNCT05487846Not applicable
• Detection of High Grade Prostate Cancer With Subharmonic Ultrasound Imaging, A Pilot StudyCompletedNCT02967458Phase 2Results posted
• A Prolonged Nightly Fasting for Men on ADT for PCaCompletedNCT07462403Not applicable
• LiSWT for Nerve Sparing Radical Prostatectomy EDCompletedNCT05877144Not applicable
• MRI Guided Radiation Therapy for the Treatment of High Risk Prostate CancerTerminatedNCT05676463Phase 2
• Prostate Cancer Diagnosis by Multiparametric Ultrasound (Wholemount)Active, not recruitingNCT05336786Phase 3
• The Peer Genetic StudyCompletedNCT05011799Not applicable
• Enhanced Genetic Awareness and Genetic Evaluation for Men Through Technology, ENGAGEMENT StudyCompletedNCT04789018
• Investigation Into Detection of Prostate Cancer Using Voided Urine (Prostate VPAC)Active, not recruitingNCT04788277
• Technology-Enhanced Acceleration of Germline Evaluation for Therapy, TARGET StudyCompletedNCT04447703Not applicable
• Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate CancerActive, not recruitingNCT02023463Phase 1